WilmerHale Advises Tidal Therapeutics in Acquisition by Sanofi

WilmerHale Advises Tidal Therapeutics in Acquisition by Sanofi

Client News

Related Solutions

Advising life sciences innovators, investors and industry leaders on complex transactions, legal issues and business challenges.
WilmerHale lawyers have decades of experience advising public and private companies in all aspects of mergers and acquisitions.

On April 9, 2021, Sanofi, a global biopharmaceutical company focused on human health, announced its acquisition of Tidal Therapeutics, a privately owned, pre-clinical stage biotech company with a novel mRNA-based approach for in vivo reprogramming of immune cells. Tidal Therapeutics utilizes technology based on proprietary nanoparticles that deliver mRNA (messages) to reprogram immune cells inside the body. The technology delivers mRNA cargos selectively to designated types of cells in the body, and will expand Sanofi’s research capabilities in both immuno-oncology and inflammatory diseases, while likely having broad applicability to other disease areas as well. Sanofi acquired Tidal Therapeutics for an upfront payment of $160 million and up to $310 million upon achievement of certain milestones.

The WilmerHale team advising Tidal Therapeutics was led by Eric Hanson and Brian Johnson, and included Ciara Baker, Steve Barrett, R. Scott Kilgore, Julie Hogan Rodgers, Michael Lopes, Meghan Fay and Gavin Tullis.

Notice

We appreciate your interest in WilmerHale. While we are pleased to have you contact us, please keep in mind that merely contacting WilmerHale does not create an attorney-client relationship. Such a relationship will not arise until the Firm agrees in writing to represent you in connection with a particular matter. Importantly, unless and until this has occurred, you should not provide us with any confidential information, and we have no duty to keep confidential any information that we may receive from you. Thank you for your understanding.

I Accept Cancel